PDCD1LG2 and neoplasm: However, high tumor PD-L2 expression also had a poor DFS prognostic value at late stages (stage III-IV) (5-year survival rates, 45.8% vs. 56.9%, log-rank test, X2 = 5.001, P=0.025, Figure 4H), while it had no prognostic value for OS and early-stage patients (Figure 4E-G).